VEGFA and breast neoplasm: CTCE-9908 reduces the growth of primary breast tumors and metastasis and markedly enhances the efficacy of other commonly used anticancer therapies such as antiangiogenic (anti-VEGF) antibody and cytotoxic agents (e.g., docetaxel) in mice breast cancer models [133,134,135].